Kinesin Family Member C1: Function in liver hepatocellular carcinoma and potential target for chemotherapeutic

Lei Liu1, Fengyang Jing2, Jia Li1

  • 1Department of General Surgery, Department of Emergency Surgery, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, Anhui, China.

Heliyon
|September 24, 2024
PubMed

Insights

MicroRNA-105 (miR-105) inhibits liver cancer progression by downregulating Kinesin Family Member C1 (KIFC1). Targeting KIFC1 offers a potential new chemotherapy strategy for liver hepatocellular carcinoma (LIHC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNA-105 (miR-105) demonstrates inhibitory roles in various cancers.
  • Decreased miR-105 expression is observed in liver cancer tissues.
  • Kinesin Family Member C1 (KIFC1) is implicated in cell division and may be a target in liver cancer.

Purpose of the Study:

  • To investigate the role of miR-105 and its target KIFC1 in liver hepatocellular carcinoma (LIHC).
  • To explore the potential of targeting KIFC1 as a chemotherapeutic strategy for LIHC.

Main Methods:

  • Analysis of The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases for differential gene expression.
  • Utilized cBioPortal, Tumor Immune Single-cell Center (TISCH) database, Gene Set Enrichment Analysis (GSEA), and R software.
  • Experimental validation including immunohistochemistry and wound healing assays.

Main Results:

  • MiR-105 directly downregulates KIFC1 expression in LIHC.
  • KIFC1 is potentially involved in DNA repair and cell cycle regulation in LIHC cells, impacting proliferation.
  • MiR-105 affects hepatoma cell proliferation through its interaction with KIFC1.

Conclusions:

  • The miR-105/KIFC1 axis plays a significant role in LIHC development and progression.
  • Targeting KIFC1 presents a promising therapeutic avenue for LIHC chemotherapy.
  • Further research into this pathway could lead to novel treatment strategies for liver cancer.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.2K